2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH SUSAN HALABI
Racial Disparities in Prostate Cancer Treatment and Outcomes

VIEW ALL PROSTATE CANCER VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH MICHAEL HOFMAN
Theranostic Approaches for Advanced Prostate Cancer

VIEW ALL IMAGING: PROSTATE VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL nmCRPC VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH MATTHEW GALSKY
Combination Approaches with Immune-Checkpoint Blockade in Bladder Cancer

VIEW ALL BLADDER CANCER VIDEOS

Featured Videos

Conferences

ASCO 2019: Vofatamab in Combination with Pembrolizumab in WT Metastatic Urothelial Carcinoma: FIERCE-22

Chicago, IL (UroToday.com) Patients with metastatic urothelial carcinoma (mUC) who have failed platinum-based chemotherapy have a poor prognosis. Currently, second-line therapies are immune checkpoint inhibitors – but reported response rates to immune checkpoint inhibitors (ICI) are approximately 20%, as seen below:

ASCO 2019: IMmotion151 Subgroup Analysis: Atezolizumab + Bevacizumab versus Sunitinib in Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Histology

Chicago, IL (UroToday.com) The landscape of systemic therapy for metastatic renal cell carcinoma (mRCC) is rapidly changing. Beyond the addition of immune checkpoint inhibitor combinations (nivo/ipi) and additional tyrosine kinase innhibitors (TKIs) (cabozantinib), there are now combination therapies that are demonstrating excellent responses rates in the first line. The recent data from KEYNOTE‑426 has led to approval of axinitib/pemrbolizumab in the first line for mRCC, and as can be expected from this combination, seems to have efficacy for good, intermediate and poor risk patients.

ASCO 2019: Patient-Reported Outcomes in IMmotion150: Atezolizumab alone or with Bevacizumab versus Sunitinib in First-Line Metastatic Renal Cell Carcinoma

Chicago, IL (UroToday.com) The landscape of systemic therapy for metastatic renal cell carcinoma (mRCC) is rapidly changing. Beyond the addition of immune checkpoint inhibitor combinations (nivo/ipi), additional TKI’s (cabozantinib), there are now combination therapies that are demonstrating excellent responses rates in the first line. The recent data from KEYNOTE‑426 has led to the approval of axinitib/pemrbolizumab in the first line for mRCC, and as can be expected from this combination, it seems to have efficacy for good, intermediate and poor risk patients.

ASCO 2019: CheckMate 214 Post-Hoc Analyses of Nivolumab plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma with Sarcomatoid Features

Chicago, IL (UroToday.com) The landscape of systemic therapy for metastatic renal cell carcinoma (mRCC) is rapidly changing. Beyond the addition of immune checkpoint inhibitor combinations (nivo/ipi), additional tyrosine kinase inhibitors (TKIs) (cabozantinib), there are now combination therapies that are demonstrating excellent responses rates in the first line.

ASCO 2019: Efficacy of Immune Checkpoint Inhibitors and Genomic Characterization of Sarcomatoid and/or Rhabdoid Metastatic Renal Cell Carcinoma

Chicago, IL (UroToday.com) The landscape of systemic therapy for metastatic renal cell carcinoma (mRCC) is rapidly changing. Beyond the addition of immune checkpoint inhibitor combinations (nivo/ipi), additional TKI’s (cabozantinib), there are now combination therapies that are demonstrating excellent responses rates in the first line. The recent data from KEYNOTE‑426 has led to the approval of axitinib/pembrolizumab in the first line for mRCC, and as can be expected from this combination, seems to have efficacy for good, intermediate and poor risk patients.

ASCO 2019: Biomarkers of Outcomes in a Randomized Phase II trial of first-line paclitaxel, ifosfamide, and Cisplatin versus Bleomycin, Etoposide, and Cisplatin for Intermediate- and Poor-Risk Germ Cell Tumors

Chicago, IL (UroToday.com) In a multicenter phase 2 randomized controlled trial of first-line Paclitaxel, ifosfamide and cisplatin (TIP) vs. bleomycin, etoposide and platinum (BEP) chemotherapy for patients with intermediate or poor risk germ cell tumor (GCT), there was no difference in the favorable response rate (FRR).1 Prior studies demonstrated the prognostic importance of tumor marker decline in advanced GCT patients receiving BEP.2-4 AKT and proteins involved in DNA damage repair (DDR) have been postulated to correlate with cisplatin sensitivity.5, 6 

ASCO 2019: Targeted Therapeutics and Patient Selection in Advanced Urothelial Carcinoma

Chicago, IL (UroToday.com) Yohann Loriot, MD, MSc, provided a summary and analysis of 3 abstracts:

Abstract 4509: A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma, Xinan Sheng
Abstract 4510: Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results, Nazli Dizman
Abstract 4511: FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis, Arlene O. Siefker-Radtke

ASCO 2019: Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy in Men with Clinically Localized, High-Risk Prostate Cancer - CALGB 90203 (Alliance)

Chicago, IL (UroToday.com) James Andrew Eastham MD, on behalf of his coauthors, presented the results of the CALGB 90203 Alliance study. He presented this earlier at AUA 2019 but presents it again to a wider audience here at ASCO 2019.

ASCO 2019: KEYNOTE-427 Cohort B: First-Line Pembrolizumab Monotherapy for Advanced Non‒Clear Cell Renal Cell Carcinoma

Chicago, IL (UroToday.com) Most renal cell carcinomas (RCC) are clear cell (80%).1 The clinical trial data for non-clear cell RCC (nccRCC) is, therefore, limited.2 The treatment guidelines for advanced nccRCC recommend enrollment in clinical trials or the use of the vascular endothelial growth factor inhibitor, sunitinib.3 There is an unmet need for a safe and effective treatment for advanced nccRCC patients. Therapies targeting the PD-1 pathway appear promising for clear cell RCC,2 but there is limited known data on the efficacy of a single agent PD-1 checkpoint inhibitor therapy in nccRCC.

ASCO 2019: First-Line Pembrolizumab Monotherapy in Advanced Clear Cell Renal Cell Carcinoma: Updated Results for KEYNOTE-427 Cohort A

Chicago, IL (UroToday.com) Interactions between programmed death 1 (PD-1) and its ligands, PD-L1, PD-L2 on tumors cells can effectively “disarm” host immune function, allowing tumors to escape immune surveillance.1 To date, several PD-1 or PD-L1 based combination regimens have received FDA approval as first-line treatment for renal cell carcinoma (RCC).2-8 The potential usefulness of a single agent PD-1 blockade in treatment-naïve clear-cell RCC (ccRCC) patients is unknown. 

ASCO 2019: A Multicentric Phase II Randomized Trial of Docetaxel plus Enzalutamide versus Docetaxel as First-line Chemotherapy for Patients with Metastatic Castration-resistant Prostate Cancer: CHEIRON Study

Chicago, IL (UroToday.com) Docetaxel and enzalutamide, along with abiraterone, are FDA approved therapies for the treatment of metastatic castration-resistant prostate cancer (mCRPC). TAX327 was the landmark study which demonstrated that docetaxel could improve overall survival, response to pain, serum PSA, and quality of life over mitoxantrone in patients with mCRPC.1

ASCO 2019: Sarcomatoid RCC: Defining a New Treatment Paradigm?

Chicago, IL (UroToday.com) James Brugarolas, MD, PhD, summarized 3 presentations — abstracts 5412, 4513, and 4514 — all focused on sarcomatoid histology within renal cell carcinoma (RCC), and in the last abstract, included rhabdoid histology.

Janssen Seeks to Expand Use of ERLEADA® (apalutamide) in the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer

San Francisco, CA (UroToday.com) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Type II variation to the European Medicines Agency (EMA) seeking approval of ERLEADA® (apalutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC), regardless of extent of disease or prior docetaxel treatment history. The submission is based on findings from the Phase 3 TITAN study which were presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published online in The New England Journal of Medicine.1,2

ASCO 2019: Clinical Outcomes According to PD-L1 Status and Age in the Prospective International SAUL Study of Atezolizumab for Locally Advanced or Metastatic Urothelial Carcinoma or Non-UC of the Urinary Tract

Chicago, IL (UroToday.com) Atezolizumab is a monoclonal antibody targeting PD-L1 that has been one of the primary immune checkpoint inhibitors leading the immune-checkpoint inhibitor (ICI) wave. In the setting of bladder cancer, it is an approved therapy for locally advanced/metastatic urothelial carcinoma (UC) based on IMvigor210 and IMvigor211 phase II and III trials.1,2

Following its approval, the single-arm SAUL3 study looked at a broader generalized patient population and found that it had a median overall survival (OS) of 8.7 months and a safety profile consistent with previous atezo trials. 

ASCO 2019: First-Line Immuno-oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International mRCC Database Consortium

Chicago, IL (UroToday.com) In metastatic renal cell carcinoma (mRCC) several first-line immuno-oncology combination therapies have been demonstrated to have improved outcomes vs. sunitinib monotherapy. Comparative data between ipilimumab/nivolumab (IPI/NIVO) and immune-oncology-VEGF (IO-VEGF) inhibitor combinations are limited. Additionally, the use and effectiveness of second-line therapies following progression on first line immune-oncology combination treatments remains unknown.

ASCO 2019: Atezolizumab + Bevacizumab Versus Sunitinib in Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Histology: IMmotion151 Subgroup Analysis - Medical Oncologist Perspective

Chicago, IL (UroToday.com) IMmotion 151 was a randomized phase III study evaluating atezolizumab plus bevacizumab versus sunitinib for patients with mRCC with either clear cell or sarcomatoid histologies. 915 patients were enrolled and 40% of patients had PD-L1 positive disease. After a median of 24 months follow up, the median progression-free survival (PFS) was 11.2 months in the atezolizumab plus bevacizumab group, compared to 7.7 months in the sunitinib group.1 In terms of overall survival (OS), there was no significant difference in the intention to treat analysis - median overall survival had a hazard ratio (HR) of 0.93 (95%CI 0.76–1.14). This abstract focuses on the subgroup of patients with sarcomatoid features on histology.

ASCO 2019: Infigratinib in Upper Tract Urothelial Carcinoma vs Urothelial Carcinoma of the Bladder and Association with Comprehensive Genomic Profiling/Cell-free DNA Results

Chicago, IL (UroToday.com) Infigratinib (BGJ398) is a potent and selective FGFR1–3 inhibitors with significant activity in patients (pts) with advanced or metastatic urothelial carcinoma (mUC) bearing FGFR3 alterations. In a study by Pal et al.1 67 cisplatin-ineligible mUC patients with FGFR3 mutations were treated with BGJ398 orally at 125 mg/day on 3 weeks on, 1 week off schedule until unacceptable toxicity or progression. Among 67 patients treated, an overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization, translating to a disease control rate of 64.2%.

ASCO 2019: Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma — CALGB 90601 (Alliance)

Chicago IL, (UroToday.com) The combination of gemcitabine and cisplatin is a standard therapy for metastatic urothelial carcinoma (mUC) based on reduced toxicity and similar outcomes as compared to MVAC. In pre-clinical models, anti-angiogenic therapies inhibit the progression of urothelial carcinoma, and vascular endothelial growth factor (VEGF) is a primary pro-angiogenic mediator of urothelial carcinoma. However, single-agent VEGF-targeted tyrosine kinase inhibitors (TKIs) have previously procedure low response rates in metastatic urothelial carcinoma.1 Bevacizumab has previously been tested in bladder cancer in a single-arm phase II study in combination with gemcitabine and cisplatin.2

ASCO 2019: Pembrolizumab for Patients with High-Risk Non–Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin: Updated Follow-Up from KEYNOTE-057

Chicago, IL (UroToday.com) Non-muscle invasive bladder cancer (NMIBC) affects about 300,000 patients per year worldwide.1 High-risk NMIBC is defined as any carcinoma in situ (CIS), T1 tumor, or high-grade Ta Tumor.2 Standard of care therapy for high-risk NMIBC is transurethral resection of bladder tumor and intravesical Bacillus Calmette-Guerin (BCG).2

ASCO 2019: Comprehensive Genomic Profiling of Upper-Tract and Bladder Urothelial Carcinoma Reveals Opportunities for Therapeutic and Biomarker Development

Chicago, IL (UroToday.com) In this poster, the authors of this multi-institutional analysis complete a thorough survey of the genomic landscape of upper tract urothelial carcinoma (UTUC) and bladder urothelial carcinoma (BUC) in an effort to better inform the development of UC therapies. This was done in the context of an increased understanding that UTUC and BUC, while both urothelial in origin, are likely distinct entities. 

gucancerssympalt Genitourinary Cancers Symposium 2014

January 30 - February 1, 2014

San Francisco Marriott Marquis
San Francisco, CA USA

24th cap update 24th Int'l. Prostate Cancer Update

February 19 - 22, 2014

Cascade Conference Center
Vail, Colorado USA

sufu x Society of Urodynamics, Female Pelvic Medicine
and Urogenital Reconstruction (SUFU) Winter Meeting

February 25 - March 1, 2014

Doral Golf Resort and Spa
Miami, Florida USA

aua ses78th Annual Meeting of the
Southeastern Section of the AUA
March 20 - 23, 2014

Hollywood, FL USA

eau29th Annual European Association
of Urology (EAU) Congress
April 11 - 15, 2014

Stockholm, Sweden

auaAmerican Urological Association (AUA)
Annual Meeting
May 16 - 21, 2014

Orlando, Florida USA

asco xAmerican Society of Clinical Oncology (ASCO)
2014 Annual Meeting

May 30 - June 3, 2014

McCormick Place
Chicago, IL USA


augs iugaAmerican Urogynecologic Society (AUGS) and
the International Urogynecological Association (IUGA)
Joint Scientific Meetings

July 22 - 26, 2014

Washington, DC USA

32nd World Congress of Endourology & SWLwce

September 3 - 7, 2014

Taipei, Taiwan

2014 Winter Meeting of the Society of Urologic Oncology (SUO)suo

"Defining Excellence in Urologic Oncology"

December 3 - 5, 2014
Bethesda, MD USA

 

 

#SUO14 - Session Highlights: Nerve sparing and template choice

read more

 

#SUO14 - Session Highlights: Choice of templates for low-stage testis cancer

read more

 

#SUO14 - Session Highlights: Minimizing morbidity of RPLND

read more

 

#SUO14 - Session Highlights: The role of SETD2 mutations in the biology of renal cell carcinoma

read more

 

#SUO14 - Session Highlights: Therapy of kidney cancer: Where are we going next?

read more

 

#SUO14 - Session Highlights: Impact of systemic therapy on characterization of peripheral circulating tumor cells in metastatic renal cell carcinoma

read more

 

#SUO14 - Session Highlights: Accelerated growth rate of multifocal tumors after initial radiofrequency ablation

read more

 

#SUO14 - Session Highlights: FSH and the metabolic syndrome

read more

 

#SUO14 - Session Highlights: Non-genomic AR pathway

read more

 

#SUO14 - Session Highlights: What is the impact of ECOG 3805 (CHAARTED) results on clinical practice?

read more

 

#SUO14 - Session Highlights: Sequencing prior to chemotherapy

read more

 

#SUO14 - Session Highlights: Cystectomy enhanced recovery pathway: Reduction in length of stay without increased morbidity or readmission

read more

 

#SUO14 - Session Highlights: Declining rate of prostate biopsy in the Veterans Health Administration in the past decade: An alternate approach to limiting overdiagnosis and overtreatment of prostate cancer?

read more

 

#SUO14 - Session Highlights: Role of 18-FDG PET/CT in staging of penile/urethral squamous cell carcinoma

read more

 

#SUO14 - Session Highlights: Trends in utilization, perioperative outcomes, and costs among open, laparoscopic, and robotic nephroureterectomies: A 10-year population-based analysis

read more

 

#SUO14 - Abstract and Poster: Decline in the use of radiation for stage I seminoma: Analysis of the National Cancer Database

read more

 

#SUO14 - Abstract and Poster: Receipt of inguinal lymph node dissection in patients with T2 penile cancer: Results from the National Cancer Database

read more

 

#SUO14 - Session Highlights: Next generation sequencing of DNA from urine detects multiple bladder tumor-derived alterations and additional changes that suggest tumor heterogeneity

read more

 

#SUO14 - Session Highlights: Is a 12-core biopsy of any value in patients with a previous negative prostate biopsy and visible lesion on magnetic resonance imaging?

read more

 

#SUO14 - Session Highlights: Histology vs. genomics: Does Gleason 3 have the hallmarks of cancer?

read more

 

#SUO14 - Session Highlights: Should MR be the standard of care before biopsy?

read more

 

#SUO14 - Session Highlights: Imaging for biochemical recurrence

read more

 

#SUO14 - Session Highlights: Long-term adverse effects in testicular cancer survivors

read more

 

#SUO14 - Session Highlights: What a urologist should do based upon long-term side effects of chemotherapy

read more

 

#SUO14 - Session Highlights: New approaches to chemotherapy in bladder cancer

read more

 

#SUO14 - Session Highlights: Management of locally advanced renal cell carcinoma and management of the adrenal gland

read more

 

#SUO14 - Session Highlights: Role of lymph node dissection in advanced RCC

read more

 

#SUO14 - Session Highlights: Management of IVC thrombi

read more

 

#SUO14 - Session Highlights: Checkpoint targeted immunotherapy

read more

 

#SUO14 - Session Highlights: The role of neoadjuvant therapy in kidney cancer patients

read more

 

#SUO14 - Session Highlights: Role of surgery for nodal oligometastatic disease in men with biochemical failure

read more

 

#SUO14 - Session Highlights: Role of post-op RT for pN+ after prostatectomy

read more

 

#SUO14 - Session Highlights: Radical prostatectomy for oligometastatic disease

read more

 

#SUO14 - Session Highlights: Targeting hormone-DNA repair crosstalk in prostate cancer: Implications for disease progression and therapeutic intervention

read more

 

#SUO14 - Session Highlights: Targeting PD-1 and PD-L1 in bladder cancer 

read more

 

#SUO14 - Session Highlights: Clinical trials of novel targeted agents

read more

 

#SUO14 - Abstract and Poster: Neoadjuvant chemotherapy is not associated with increased risk of perioperative complications, mortality, nor readmission rates in patients undergoing radical cystectomy

read more

 

#SUO14 - Abstract and Poster: Declining rates of retroperitoneal lymph node dissection for stage I non-seminomatous germ cell tumors: Results from the National Cancer Database

read more

 

#SUO14 - Session Highlights: Declining rates of retroperitoneal lymph node dissection for stage I non-seminomatous germ cell tumors: Results from the National Cancer Database

read more

 

#SUO14 - Abstract and Poster: Surgical Apgar score predicts an increased risk for death and readmission following radical cystectomy

read more

 

#SUO14 - Abstract and Poster: Surgical Apgar score and nephrometry score predict increased risk for major complication and death following renal mass excision

read more

 

#SUO14 - Session Highlights: New insights into bladder cancer subtyping

read more

 

#SUO14 - Session Highlights: Genetic findings in invasive bladder cancer: Recent Data and clinical implications

read more

 

#SUO14 - Session Highlights: Epigenetic control of bladder cancer heterogeneity by non-coding RNAs

read more

 

#SUO14 - Session Highlights: Towards a molecular genetic and functional classification of renal cancer

read more

 

#SUO14 - Session Highlights: Biology of bladder cancer metastasis

read more

 

#SUO14 - Session Highlights: Challenges and opportunities facing tumor and therapeutic heterogeneity of kidney cancer

read more

 

#SUO14 - Session Highlights: RCC tumor ontogeny – lessons from the small renal mass

read more

 

#SUO14 - Session Highlights: Optimal targeting of the PD-1/PDL-1 pathway in metastatic renal cell carcinoma

read more

 

gucancerssympalt Genitourinary Cancers Symposium 2015

February 26 - 28, 2015

Rosen Shingle Creek
Orlando, FL USA

 

 

 #GU15 - Androgen deprivation therapy, cardiovascular risk, and multidisciplinary management of the prostate cancer patient: A German perspective - Session Highlights

read more

 

#GU15 - AR splice variant 7 (AR-V7) could be a marker for treatment selection in metastatic castrate-resistant prostate cancer

read more

 

#GU15 - Novel imaging modalities boost detection of early metastatic disease in prostate cancer - Session Highlights

read more

 

#GU15 - Progress and challenges in penile, urethral, and testicular cancer - Session Highlights

read more

 

#GU15 - Prostate cancer in 2014- 2015: Advances and ongoing challenges in therapeutics, biomarkers, and precision medicine

read more

 

#GU15 - Renal cell cancer keynote: Management of RCC: Future needs and opportunities - Session Highlights

read more

 

#GU15 - Year in review: Renal cell cancer - Session Highlights

read more

 

#GU15 - Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial - Session Highlights

read more

 

#GU15 - Metabolic pathways - Session Highlights

read more

 

#GU15 - Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy (NAC) in urothelial carcinoma - Session Highlights

read more

 

#GU15 - Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience - Session Highlights

read more

 

#GU15 - Correlation of baseline serum testosterone and PSA at 7 months in patients with new metastatic prostate cancer treated with continuous ADT - Session Highlights

read more

 

#GU15 - Treatment patterns of new metastatic castration-resistant prostate cancer (mCRPC) therapies: Real-world evidence from three datasets - Session Highlights

read more

 

#GU15 - AR modulation optimized for response in splice variant (ARMPR3-SV): A RCT of galeterone vs enzalutamide in men expressing ARv7 in mCRPC - Session Highlights

read more

 

#GU15 - Poster: Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel subgroup

read more

 

#GU15 - Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel subgroup - Session Highlights

read more

 

#GU15 - Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting - Session Highlights

read more

 

#GU15 - Radium-223 dichloride (Ra-223) in U.S. Expanded Access Program (EAP) - Session Highlights

read more

 

#GU15 - Association between PSA declines at 4 weeks and OS in patients treated with abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC) after docetaxel - Session Highlights

read more

 

#GU15 - Effect of early detection of asymptomatic visceral recurrence after radical cystectomy on prognosis in patients with muscle invasive bladder cancer - Session Highlights

read more

 

#GU15 - Effect of early detection of asymptomatic visceral recurrence after radical cystectomy on prognosis in patients with muscle invasive bladder cancer - Session Highlights

read more

 

#GU15 - Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone - Session Highlights

read more

 

#GU15 - Urothelial carcinoma keynote - Session Highlights

read more

 

#GU15 - Exploring the effects of abiraterone/enzalutamide failure prior to the initiation of radium-223 dichloride in men with metastatic castrate-resistant prostate cancer - Session Highlights

read more

 

#GU15 - The impact of time to metastasis on survival in treatment-naïve prostate cancer patients - Session Highlights

read more

 

#GU15 - A multidisciplinary clinic to mitigate the impact of androgen deprivation therapy in prostate cancer: A pilot study - Session Highlights

read more

 

#GU15 - Contemporary use of radium-223 (Ra-223) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Feasibility and safety - Session Highlights

read more

 

#GU15 - Best of journals: mCRPC treatment - Session Highlights

read more

 

#GU15 - Urothelial carcinoma: Year in review - Session Highlights

read more

 

#GU15 - The biology of bladder cancer metastasis - Session Highlights

read more

 

#GU15 - What is new in systemic therapy for urothelial tumors? - Session Highlights

read more

 

#GU15 - Best of journals: Prostate cancer - Session Highlights

read more

 

#GU15 - Best of journals - Session Highlights

read more

 

#GU15 - Dynamic changes in biomarkers for immune response to sipuleucel-T for mCRPC - Session Highlights

read more

 

#GU15 - FANCA loss as a biomarker of platinum sensitivity in prostate cancer - Session Highlights/span>

read more

 

#GU15 - Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014 - Session Highlights

read more

 

#GU15 - Are patients with Gleason 6 pathology safe from developing metastatic castration-resistant prostate cancer (mCRPC)? - Session Highlights

read more

 

#GU15 - Testosterone levels in metastatic castration resistant prostate cancer (mCRPC) - Session Highlights

read more

 

#GU15 - Poster: 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from ALSYMPCA

read more

  

#GU15 - 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from ALSYMPCA - Session Highlights

read more

 

#GU15 - Place of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy: A phase III trial - Session Highlights

read more

 

#GU15 - Prostate Cancer Keynote: Can epigenetic alterations in human cancers be exploited for cancer screening, detection, diagnosis and treatment? - Session Highlights

read more

 

#GU15 - Prostate cancer: Year in review - Session Highlights

read more

 

#GU15 - ASCENDE-RT: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer - Session Highlights

read more

 

#GU15 - ADT plus docetaxel versus ADT alone for hormone-naïve metastatic prostate cancer: Long-term analysis of the GETUG-AFU 15 phase III trial - Session Highlights

read more

 

#GU15 - Characterization of abiraterone responses in African American men with castrate resistant prostate cancer - Session Highlights

read more

 

#GU15 - Effects of radium-223 dichloride with docetaxel (D) versus D on PSA and bone alkaline phosphatase in patients with castration-resistant prostate cancer and bone metastases: A phase 1/2a clinical trial - Session Highlights

read more

 

#GU15 - Poster: Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302

read more

 

#GU15 - Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302 - Session Highlights

read more

 

#GU15 - Poster: External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial

read more

 

#GU15 - External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial - Session Highlights

read more

 

#GU15 - Quantitative total bone imaging (QTBI) in patients with metastatic castration-resistant prostate cancer (CRPC) using NaF PET/CT - Session Highlights

read more

 

#GU15 - AR-based biomarker association with response to abiraterone in mCRPC - Session Highlights

read more

 

#GU15 - Antigen-specific immune responses through 24 months in the STAND trial: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer - Session Highlights

read more

 

#GU15 - Assessment of corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate in mCRPC - Session Highlights

read more

 

#GU15 - Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: Exploratory analysis of a randomized controlled trial - Session Highlights

read more

 

#GU15 - Increase in higher risk prostate cancer cases following new screening recommendation by the US Preventive Services Task Force (USPSTF) - Session Highlights

read more

 

#GU15 - Early radiation response between GnRH agonist versus antagonist combined with radiotherapy in high-risk prostate cancer - Session Highlights

read more

 

#GU15 - Impact of CCP test on personalizing treatment decisions: Results from a prospective registry of newly diagnosed prostate cancer patients - Session Highlights

read more

 

#GU15 - Abstract highlights: AR splice variant 7 (AR-V7) and response to taxanes in men with mCRPC - Session Highlights

read more

 

#GU15 - Bench to bedside: Androgen resistance - Session Highlights

read more

 

#GU15 - Clinical context: Using new imaging modalities to identify early metastatic disease - Session Highlights

read more

 

#GU15 - Role of local therapy - Session Highlights

read more

 

#GU15 - A multi-institutional prospective trial in the United States confirms the 4K Score accurately identifies men with high-grade prostate cancer - Session Highlights

read more

 

#GU15 - Biomarkers for prostate cancer: Why aren’t we using them and where do we go from here? - Session Highlights

read more

 

#GU15 - Hormonal therapy: How long is enough? - Session Highlights

read more

 

#GU15 - Who can receive shorter-course radiotherapy? Hypofractionation and stereotactic body radiation therapy - Session Highlights

read more

 

#GU15 - Individualized treatment decisions for localized prostate cancer: Decision aids and quality of life outcomes - Session Highlights

read more

 

Bayer presents latest oncology research at ASCO GU 2015

read more

 

Early evidence of increase in higher-risk prostate cancers from 2011-2013

read more

 

Active surveillance of intermediate-risk prostate cancer associated with decreased survival

read more

 

Men who have had testicular cancer are more likely to develop prostate cancer, although overall risk of developing aggressive disease is low

read more

 

 

Adjuvant sorafenib and sunitinib do not improve outcomes in locally advanced kidney cancer

read more

 

 

Androgen receptor abnormality may not be associated with primary resistance to taxane chemotherapy

read more

 

 

 

auaAmerican Urological Association (AUA)
Annual Meeting
May 15 - 19, 2015

New Orleans, Louisiana USA



asco xAmerican Society of Clinical Oncology (ASCO)
2015 Annual Meeting

May 29 - June 2, 2015

McCormick Place
Chicago, IL USA


Winter Meeting of the Society of Urologic Oncology (SUO)suo

"Defining Excellence in Urologic Oncology"

December 2 - 4, 2015
Washington, DC USA

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe